Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Rexahn Pharmaceuticals, Inc. ("Rexahn" or the "Company") (NASDAQ: REXN) to Ocuphire Pharma, Inc. ("Ocuphire"). Under the terms of the merger, Ocuphire will merge with a wholly-owned subsidiary of Rexahn, with Ocuphire surviving the merger as a wholly-owned subsidiary of Rexahn. Following the merger, the combined company will change its name to Ocuphire Pharma, Inc. and is expected to trade on the Nasdaq Capital Market under the ticker symbol “OCUP.” Rexahn’s then-current stockholders would own approximately 14.3% of the combined company’s common stock, and the former Ocuphire securityholders would own approximately 85.7% of the combined company’s common stock, in each case calculated on a fully-diluted basis.
The Rexahn The merger investigation concerns whether the Board of Rexahn has harmed stockholders by agreeing to enter into this transaction and whether all material facts have been properly disclosed to stockholders.
To receive more information, please fill out the form.